IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12077519 B1

PDFFull Text
Date of Patent:
Sep. 03, 2024

Filed:

Nov. 28, 2023

Heteroaryl carboxamide compound

Applicants:

Astellas Pharma Inc., Tokyo, JP;

Kotobuki Pharmaceutical Co., Ltd., Nagano, JP;

Inventors:

Hideyuki Watanabe, Tokyo, JP;

Takashi Kamikubo, Tokyo, JP;

Akio Kamikawa, Tokyo, JP;

Takuya Washio, Tokyo, JP;

Yohei Seki, Tokyo, JP;

Keiichiro Okuyama, Tokyo, JP;

Osamu Ikeda, Tokyo, JP;

Hiroshi Tomiyama, Nagano, JP;

Yoshinori Iwai, Nagano, JP;

Akihiko Nakamura, Nagano, JP;

Kozo Miyasaka, Nagano, JP;

Assignees:

Astellas Pharma Inc., Tokyo, JP;

KOTOBUKI PHARMACEUTICAL CO., LTD., Nagano, JP;

Attorneys:

McCarter & English, LLP

Wei Song

James M. Alburger

Primary Examiner:

Noble E Jarrell

Int. Cl.
CPC ...
C07D 401/12 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/501 (2006.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/501 (2013.01); A61K 31/519 (2013.01); A61P 35/00 (2018.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01); C07D 487/04 (2013.01);
Abstract

A compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy is provided. The present inventors have conducted studies on a compound useful as an active ingredient of a pharmaceutical composition for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy, and confirmed that a heteroaryl carboxamide compound has DGK ξ (DGKzeta) inhibitory effect, leading to completion of the present invention. The heteroaryl carboxamide compound of the present invention has DGK ξ inhibitory effect, and can be used as a therapeutic agent for treatment of cancer related to activation of immune cells or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy.

Find Patent Forward Citations

Loading…